Φορτώνει......
BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer
PARP inhibition is known to be an effective clinical strategy in BRCA-mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here we show synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastrophe. Treatment o...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cell Rep |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5745042/ https://ncbi.nlm.nih.gov/pubmed/29262321 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2017.11.095 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|